Cytomegalovirus infection in malignant pleural mesothelioma

PLoS One. 2021 Aug 12;16(8):e0254136. doi: 10.1371/journal.pone.0254136. eCollection 2021.

Abstract

Human cytomegalovirus (HCMV) is a highly prevalent herpes virus which persists as a latent infection and has been detected in several different tumor types. HCMV disease is rare but may occur in high-risk settings, often manifesting as a pulmonary infection. To date HCMV has not been investigated in malignant pleural mesothelioma (MPM). In a consecutive case series of 144 MPM patients we evaluated two biomarkers of HCMV: IgG serostatus (defined as positive and negative) and DNAemia (>100 copies/mL of cell free HCMV DNA in serum). Approximately half of the MPM patient population was HCMV IgG seropositive (51%). HCMV DNAemia was highly prevalent (79%) in MPM and independent of IgG serostatus. DNAemia levels consistent with high level current infection (>1000 copies/mL serum) were present in 41% of patients. Neither IgG serostatus nor DNAemia were associated with patient survival. In tissues, we observed that HCMV DNA was present in 48% of tumors (n = 40) and only 29% of normal pleural tissue obtained from individuals without malignancy (n = 21). Our results suggest nearly half of MPM patients have a high level current HCMV infection at the time of treatment and that pleural tissue may be a reservoir for latent HCMV infection. These findings warrant further investigation to determine the full spectrum of pulmonary infections in MPM patients, and whether treatment for high level current HCMV infection may improve patient outcomes.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Antibodies, Viral / blood*
  • Cytomegalovirus / metabolism*
  • Cytomegalovirus Infections / blood
  • Cytomegalovirus Infections / mortality
  • DNA, Viral / blood*
  • Disease-Free Survival
  • Female
  • Humans
  • Immunoglobulin G / blood*
  • Male
  • Mesothelioma, Malignant* / blood
  • Mesothelioma, Malignant* / mortality
  • Mesothelioma, Malignant* / virology
  • Middle Aged
  • Pleural Neoplasms* / blood
  • Pleural Neoplasms* / mortality
  • Pleural Neoplasms* / virology
  • Pneumonia, Viral* / blood
  • Pneumonia, Viral* / mortality
  • Pneumonia, Viral* / virology
  • Retrospective Studies
  • Survival Rate

Substances

  • Antibodies, Viral
  • DNA, Viral
  • Immunoglobulin G